Cushing syndrome caused by the body’s own overproduction of cortisol is genuinely rare, affecting roughly 2 to 8 people per million each year. To put that in perspective, in a city of one million residents, fewer than 10 would be diagnosed in a given year. However, recent data from a Wisconsin-based study suggests the true number may be higher, potentially around 11 cases per million per year, because many cases go unrecognized or take years to diagnose.
Endogenous vs. Medication-Induced Cases
There are two broad categories of Cushing syndrome, and they differ dramatically in how common they are. The endogenous form, where the body produces too much cortisol on its own, is the rare one. The far more common version is iatrogenic Cushing syndrome, caused by taking steroid medications like prednisone or hydrocortisone for other conditions such as asthma, autoimmune diseases, or organ transplants. Anyone on high-dose steroids for an extended period can develop Cushing features. When doctors describe Cushing syndrome as “rare,” they’re almost always referring to the endogenous form.
How the Different Causes Break Down
Among people with endogenous Cushing syndrome, the most common cause is a small, benign tumor on the pituitary gland that overproduces a hormone signaling the adrenal glands to churn out cortisol. This specific form is called Cushing disease (with “disease” reserved for the pituitary cause). A large Swedish study spanning over 25 years found Cushing disease occurs at a rate of about 1.6 cases per million people per year, and it accounts for roughly 60 to 70% of all endogenous cases.
About 20% of endogenous cases come from problems in the adrenal glands themselves, most often a benign adrenal tumor. Adrenal cancers that produce cortisol are rarer still. A recent Wisconsin study found a surprisingly high proportion of adrenal cases (60% of their patients), which may reflect improved imaging technology catching tumors that would have gone undetected in earlier decades.
The remaining 5 to 20% of cases are caused by tumors elsewhere in the body, often in the lungs or pancreas, that produce the same signaling hormone the pituitary normally makes. These ectopic cases can be especially difficult to locate and diagnose.
Who Gets It
Cushing syndrome overwhelmingly affects women more than men. The female-to-male ratio ranges from 3:1 to as high as 8:1 depending on the study, with most research landing around 4 or 5 women for every man diagnosed. The typical age at diagnosis is around 30 to 35, though it can appear at any age.
In children, Cushing syndrome is exceptionally rare. Only about 10% of all new endogenous cases occur in people under 18, translating to roughly 1 case per million children per year. Because so few pediatric specialists ever encounter it, diagnosis in children is particularly challenging. The condition can disrupt growth, puberty, bone density, and psychological health in ways that don’t apply to adults.
Why It Often Takes Years to Diagnose
Part of what makes Cushing syndrome seem rarer than it may actually be is how long diagnosis takes. Survey data from patients found that the median time from first symptoms to a confirmed diagnosis was about 2.9 years for Cushing syndrome overall, and 4.3 years for pituitary-driven Cushing disease specifically. Many symptoms, like weight gain, fatigue, high blood pressure, mood changes, and irregular periods, overlap with far more common conditions. Doctors may treat each symptom individually for years before recognizing the pattern.
This diagnostic delay means some people live with undiagnosed Cushing syndrome for a significant portion of their lives. It also means that official incidence numbers (2 to 8 per million) likely undercount the real burden. The Wisconsin study that estimated 11 cases per million per year supports this idea, suggesting that as awareness and testing improve, more cases surface.
Rare, but Not as Rare as Once Thought
European population studies from earlier decades estimated endogenous Cushing syndrome at 1.5 to 3.2 cases per million per year. More recent work is revising that number upward. Better imaging, wider use of screening tests, and growing clinical awareness all contribute to higher detection rates. The condition remains uncommon by any measure, but the gap between “textbook rare” and real-world occurrence appears to be narrowing as medicine catches up with the disease.